Minireview

Peroxisome Proliferator-activated Receptor Modulators As Potential Chemopreventive Agents

Levy Kopelovich,1 Judith R. Fay, Robert I. Glazer, and James A. Crowell

National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland 20892-7322 [L. K., J. R. F., J. A. C.], and Department of Pharmacology, Georgetown University School of Medicine, Washington, D.C. 20057 [R. I. G.]

Abstract

Peroxisome proliferator-activated receptors (PPARs), members of the superfamily of nuclear steroid hormone receptors, have traditionally been studied for their role in lipid, glucose, and energy homeostasis. Recent evidence suggests that pharmacological activation of PPARγ and PPARα, and inhibition of PPARδ, may prevent cancer. PPARγ agonists induce differentiation, inhibit the growth of established tumor cells in vitro and in vivo, and have chemopreventive effects in animal models. PPARα has anti-inflammatory and differentiating activity and protects against the oxidative damage associated with aging. In contrast, PPARδ expression may be a factor in colorectal carcinogenesis. PPARδ is normally repressed by the adenomatous polyposis coli tumor suppressor gene, and impaired adenomatous polyposis coli is strongly associated with human colorectal cancer risk. This review presents a rationale for using PPAR modulators as cancer chemopreventive drugs.

Introduction

PPARs2 are ligand-activated transcription factors that heterodimerize with the RXRs and bind to peroxisomal proliferator response elements in the promoter region of target genes. Three PPAR isoforms have been cloned (α, γ, and δ), each exhibiting distinct patterns of tissue distribution and ligand specificity. PPARα regulates numerous aspects of fatty acid catabolism, whereas PPARγ controls adipocyte differentiation, systemic glucose levels, and lipid homeostasis (reviewed in Refs. 1 and 2). PPARδ is involved in development, embryo implantation, myelination of the corpus callosum, lipid metabolism, and epidermal cell proliferation (3, 4). Significant species differences in response to PPARα, but not PPARγ, have been noted. Specifically relevant to cancer, PPARα agonists increase peroxisomes and induce hepatomegaly and liver cancer in rodents. However, humans are refractory to the hepatotoxic actions of these drugs (reviewed in Ref. 5). In the following sections, evidence is presented for each PPAR class and the specific PPAR agonists that may play a role in cancer chemoprevention.

PPARγ and Cancer

The observation that PPARγ stimulates adipose differentiation in cultured mouse fibroblasts generated interest in the receptor’s potential anticancer effects (6). Subsequent studies showed that activation of the receptor inhibits proliferation, and in some cases induces differentiation and/or apoptosis, in a variety of tumor cell lines (Table 1). Some of the most extensive work has been conducted in the colon, where PPARγ is expressed at high levels in normal tissue (7), and in both well- and poorly differentiated colon cancers (8). PPARγ-selective ligands inhibit proliferation and induce differentiation in colon cancer cell lines (8, 9) and diminish growth of human colon tumor xenografts (Ref. 8; Table 2). Importantly, for the purposes of chemoprevention, these ligands prevent the development of carcinogen-induced preneoplastic aberrant crypt foci in rats (10). Loss-of-function somatic mutations in the PPARγ gene are found in sporadic human colon cancers, suggesting that PPARγ may function directly as a tumor suppressor (11). PPARγ agonists also suppress macrophage activation and inflammatory cytokine production in vitro (12, 13) and reduce inflammation (10, 14) and neoplastic lesion development (10) in rodent models of inflammatory bowel disease. The latter finding is particularly relevant to chemoprevention, because the risk of colorectal cancer is increased in patients with this disease (reviewed in Ref. 15).

In contrast, other studies indicate that PPARγ activation promotes colon cancer in mice carrying a nonsense mutation in the APC tumor suppressor gene; defective APC is highly associated with human colorectal cancer risk (16). The TZDs troglitazone and rosiglitazone enhance colon tumorigenesis in these genetically predisposed mice; the more potent PPARγ agonist rosiglitazone induces more malignant tumors. However, pharmacological doses of troglitazone are not tumorigenic in wild-type mice, suggesting that increased risk is limited to animals harboring a mutant APC gene (17, 18).

Data available from other target sites suggest that PPARγ activation has chemopreventive potential. The receptor is expressed in human breast cancer cell lines and breast adenocarcinomas, and TZDs inhibit growth of breast cancer cells in vitro and in vivo, inducing differentiation in some cases (19, 20). However, cell lines expressing the highest levels of PPARγ are relatively unresponsive to TZD treat-
ment. Adding a mitogen-activated protein kinase inhibitor overcomes this insensitivity, suggesting that phosphorylation prevents PPARγ activation (19).

The relevance of PPARγ activation for chemoprevention has been demonstrated in rodent mammary cancer models. The highly potent and specific PPARγ ligand GW 7845 significantly reduces tumor incidence, number, and weight in estrogen receptor-positive mammary tumors when fed to rats after carcinogen administration. Additive effects are observed on coadministration with suboptimal doses of the antiestrogen tamoxifen (21). Likewise, troglitazone prevents development of carcinogen-induced early neoplastic lesions in mouse mammary gland organ culture (31). Furthermore, PPARγ ligands also diminish expression of aromatase (23), the rate-limiting enzyme in estrogen biosynthesis, which may contribute to chemopreventive effects in estrogen-responsive tissues.

In the prostate, PPARγ is expressed in primary cancers and cell lines, and receptor agonists display antiproliferative effects in vitro (24–26) and in xenografts in nude mice (24); effects in vivo are associated with necrotic, as well as apoptotic changes (24). Additionally, a subset of human prostate tumors carry hemizygous deletions of the PPARγ gene (25). In preliminary clinical studies, 20% (8 of 41) of prostate cancer patients treated with troglitazone showed decreased serum prostate-specific antigen levels, and 39% showed prolonged stabilization (25). Consistent with these findings, troglitazone decreases prostate-specific antigen levels in prostate cancer cell lines (24, 25). The actions of PPARγ ligands in the prostate may be associated with decreased activation of the androgen receptor (27) or a reduction in circulating estrogens (reviewed in Ref. 28), secondary to inhibition of tumor cell growth, metastasis, and angiogenesis (30), markedly decreases in lung cancer cells treated with PPARγ ligands also inhibit proliferation of human lung, urinary bladder, pancreatic, neuroblastoma, gastric, and liposarcoma cell lines (Table 1) and induce differentiation and inhibit growth of liposarcomas in patients (29). The activated form of matrix metalloproteinase-2, strongly associated with tumor growth, metastasis, and angiogenesis (30), markedly decreases in lung cancer cells treated with PPARγ agonists (31). Furthermore, PPARγ activators are direct inhibitors of angiogenesis both in vitro and in vivo (32, 33). A role for PPARγ in thyroid follicular carcinoma is suggested by the presence in these tumors of a PAX8-PPARγ1 fusion oncoprotein, which functions as a dominant negative suppressor of wild-type PPARγ (34).

Recent investigations have provided clues about the signaling pathways used by PPARγ agonists to suppress neoplasia. Inhibition of tumor cell growth has been associated with G1 cell cycle arrest (9, 35, 36), which in some cases is linked to loss of DNA binding activity of the transcriptional regulator E2F/DP (37). Other mechanisms that may be involved include up-

### Table 1 Antiproliferative effects of PPARγ ligands in vitro*

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Cell Line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Troglitazone</td>
<td>Bladder [39], breast [19, 20], colon [8, 9], lung [78], hematopoietic system [79], pancreas [36], prostate [24, 25], stomach [80]</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>Colon [8, 9], prostate [24, 25, 81]</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>Breast [19], colon [8], liposarcoma [82], hematopoietic system [79], stomach [80]</td>
</tr>
<tr>
<td>Ciglitazone</td>
<td>Lung [31], prostate [26]</td>
</tr>
<tr>
<td>GW 1929</td>
<td>Neuroblastoma [83]</td>
</tr>
<tr>
<td>15d-PGJ2b</td>
<td>Breast [84], colon [8], lung [31, 78], prostate [24, 25, 26], neuroblastoma [83]</td>
</tr>
</tbody>
</table>

* Growth inhibitory effects of PPARγ ligands in cancer cell lines, sometimes accompanied by induction of differentiation, apoptosis, and/or cell cycle arrest.

** 15d-PGJ2, 15-deoxy-Δ12,14-prostaglandin J2.
regulation of the cyclin-dependent kinase inhibitors p18\textsuperscript{INK4c} and p21\textsuperscript{Waf1/Cip1} and reduced expression of cyclin D1 (31–40). Recent studies showed that the antiproliferative and anti-inflammatory activities of PPAR\gamma ligands are mechanistically distinct. PPAR\gamma-dependent antiproliferative effects involve repression of cyclin D1 via sequestration of p300 and interference with c-fos-directed transcription. Anti-inflammatory effects, independent of this receptor, are mediated via inhibition of the intracellular kinase intracellular B kinase, involved in nuclear factor \kappa B activation (40). Additionally, PPAR\gamma agonists up-regulate the phosphatase and tension homologue (PTEN) tumor suppressor, suggesting that phosphoinositide signaling pathways are also associated with PPAR\gamma-mediated growth suppression (41).

**PPAR\alpha and Cancer**

Several studies have established a link between PPAR\alpha activation and epidermal differentiation. Fibrates, which are PPAR\alpha ligands, induce differentiation and inhibit proliferation of human keratinocytes \textit{in vitro} (42), and in normal (43) and hyperproliferating (44) mouse skin \textit{in vivo}, but are inactive in PPAR\alpha-deficient mice (43). Farnesol also stimulates PPAR\alpha-dependent differentiation in epidermal keratinocytes (45). Topical PPAR\alpha agonists have weak preventive effects on tumor promotion in mouse skin, despite up-regulation of PPAR\alpha in untreated tumors compared with normal epidermis (46). In this regard, PPAR\alpha expression is also up-regulated in human prostate adenocarcinomas (47). The significance of this observation is as of yet unknown.

---

*Fig. 1. Chemical structures of PPAR modulators.*
Some anticancer actions of phenylacetate may be mediated by PPARα activation. The relative potencies of phenylacetate and its analogues as PPARα activators correlate strongly to their growth inhibitory effects in human cancer cell lines (48). Phenylacetate also activates PPARγ (49), making it difficult to ascribe growth-inhibitory effects specifically to activation of the α isoform. It is important to note that PPARα ligands are inactive in tumor cell lines in which PPARγ ligands are effective antiproliferative agents (8, 9, 25); however, the status of PPARα expression in these tumor cell lines is unknown.

In rodents, PPARα activation has been associated with both anti- (50, 51) and proinflammatory (52) actions. Opposing effects have also been described in humans. PPARα agonists diminish expression of inflammatory markers in human cells and patients treated with fibrates (53, 54). In contrast, expression of the inflammatory mediator COX-2 in human breast and colon cancer cells is up-regulated by PPARα agonists (55). The latter finding is particularly troublesome, given that increased COX-2 expression has been specifically linked to enhanced colon cancer risk (reviewed in Ref. 28).

Other possible connections between PPARα and cancer prevention come from the inverse association of PPARα activation with decreased oxidative stress and aging, both linked with tumorigenesis (reviewed in Ref. 56). PPARα agonists administered to aged PPARα-null mice, decreased tissue levels of lipid peroxides and the oxidant-stress-activated transcription factor nuclear factor κB (51). Additionally, reduced expression of PPARα and peroxisome-associated genes is observed in aged mice; PPARα agonists restore expression to levels seen in young animals (57).

PPARδ and Cancer

In contrast to the γ and α isoforms, activation of PPARδ is associated positively with tumorigenesis. PPARδ transcription is normally suppressed by wild-type APC but is up-regulated in colorectal cancer cells, which have an inactivating APC mutation through enhanced β-catenin/Tcf-4 binding to TCF-4-responsive elements in the PPARδ promoter (58). Xenografts of PPARδ-null colon cancer cell lines display decreased tumorigenicity in nude mice (59). Consistent with these findings, PPARδ is overexpressed in human and rodent colorectal tumors, as well as preneoplastic colonic mucosa (58, 60, 61). Although initial experiments suggested that nonsteroidal anti-inflammatory drug-induced apoptosis is mediated in part by PPARδ inhibition (58), this was not confirmed in additional studies (59). However, additional experiments in PPARδ-null mice indicate that nonsteroidal anti-inflammatory drug-mediated anti-inflammatory response, which may also be chemopreventive, is at least partially dependent on PPARδ (3).

PPAR Modulators

As suggested by the data presented above (Fig. 1), agonists of PPARγ and PPARα, and antagonists of PPARδ, may find utility as chemopreventive agents. Although no selective PPARδ inhibitors have been identified, a number of agonists for these isoforms has been described. Selective PPARγ agonists include classic TZDs (troglitazone, rosiglitazone, pioglitazone, and ciglitizone; Refs. 62 and 63) and non-TZD-type agonists. Representatives of the latter include N-(2-benzoylphenyl)-L-tyrosine derivatives, such as GW 1929, Gl 262570, and GW 7845, which are among the most potent and selective PPARγ agonists identified to date (64, 65). GW 20207, a 2,3-disubstituted indole-5-carboxylic acid, is also a potent and selective PPARγ agonist (66).

Fibrates are weak PPARα agonists used to treat hyperlipidemia (2). Newer PPARα agonists, such as the ureidofibrate GW 9578, are significantly more potent (67) and can be used to study the effects of PPARα in neoplasia. If both PPARα and PPARγ are involved in tumorigenesis, dual receptor agonists, such as the TZD KRP-297 (68) and the related isoazolidinedione derivative JTT-501 (69), may also find utility as chemopreventive agents.

The following compounds can act as partial PPARγ agonists/antagonists. Although TZD MCC-555 is a low-affinity PPARγ ligand, it is an effective PPARγ activator in animals (70). L-764406, a sulfonyl quinoxaline derivative, is a potent and specific PPARγ ligand and partial agonist that covalently modifies the receptor (71). The thiazolidine acetamide GW 0072 is a high-affinity PPARγ ligand and weak partial transcriptional activator of the receptor; it is also a potent inhibitor of rosiglitazone-induced adipocyte differentiation (72).

These partial agonists/antagonists display unique biological properties that may translate to distinct therapeutic and/or toxicological profiles, similar to selective estrogen receptor modulators (partial estrogen receptor agonists/antagonists; reviewed in Ref. 28). This is significant, because the selective PPARγ agonist troglitazone can have rare but serious hepatotoxic consequences (73). Moreover, it is possible that the cancer-promoting effects of PPARγ ligands, as observed in animals predisposed to colon cancer, can be mitigated using partial agonists.

Conclusions

The PPAR system’s relevance to carcinogenesis is just beginning to be unraveled. Additional research is needed to characterize expression patterns of the various PPAR isoforms in cancerous and precancerous tissue and to determine their precise roles in the carcinogenic process. Numerous fatty acids and their metabolites activate PPAR receptors (74, 75). Thus, PPARs may also provide the missing molecular link between high-fat diets and nutritionally sensitive cancers (76). Although the physiological function of the PPAR was once thought to be restricted to lipid metabolism, it is now clear that these receptors are involved in numerous biological processes. Confirming a crucial role for PPARs in tumorigenesis will foster development of a novel class of cancer preventive drugs (77).

References


Erratum

In the article by Kopelowich et al., entitled “Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents,” which appeared in the March 2002 issue of MCT (pp. 357–363), Dr. Judith R. Fay’s affiliation was listed incorrectly as National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892-7322. Dr. Fay’s correct affiliation is CCS Associates, Mountain View, California 94043.
Molecular Cancer Therapeutics

Peroxisome Proliferator-activated Receptor Modulators As Potential Chemopreventive Agents


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/1/5/357

Cited articles
This article cites 83 articles, 38 of which you can access for free at:
http://mct.aacrjournals.org/content/1/5/357.full#ref-list-1

Citing articles
This article has been cited by 17 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/1/5/357.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.